Correspondence 0001683168-23-008984 from CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: Dec. 20, 2023 · CIK: 0001729427 · Accession: 0001683168-23-008984
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275973
Letter
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
December 20, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-1 (the “Registration Statement”)
File No. 333-275973
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00 P.M. (Eastern Time) on December 21, 2023, or as soon thereafter as possible on such date.
We request that we be notified of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness also be confirmed in writing.
Very truly yours,
CNS Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027
December 20, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: CNS Pharmaceuticals, Inc.
Registration Statement
on Form S-1 (the “Registration Statement”)
File No. 333-275973
Ladies and Gentlemen:
Pursuant to Rule 461 of the
Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests
that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 5:00
P.M. (Eastern Time) on December 21, 2023, or as soon thereafter as possible on such date.
We request that we be notified
of such effectiveness by a telephone call to Cavas Pavri at (202) 724-6847 of ArentFox Schiff LLP, and we request that such effectiveness
also be confirmed in writing.
Very truly yours,
CNS Pharmaceuticals, Inc.
By: /s/ Christopher Downs
Name: Christopher Downs
Title: Chief Financial Officer
cc: Cavas Pavri, ArentFox Schiff LLP